

METHOTREXAT "EBEWE"

10 mg/ml and 100 mg/ml solution for injection & infusion

Composition

Vials

1 vial of 5 ml contains: 50 mg methotrexate
1 vial of 5 ml contains: 500 mg methotrexate
1 vial of 10 ml contains: 1000 mg methotrexate
1 vial of 50 ml contains: 5000 mg methotrexate

Pre-filled Syringes

1 pre-filled syringe of 0.75 ml contains 7.5 mg methotrexate
1 pre-filled syringe of 1.00 ml contains 10.00 mg methotrexate
1 pre-filled syringe of 1.50 ml contains 15.00 mg methotrexate
1 pre-filled syringe of 2.00 ml contains 20.00 mg methotrexate

Clinical Particulars

Indications

Antineoplastic Chemotherapy: Treatment of gestational choriocarcinoma, chorioadenoma destruens and hydatidiform mole. Palliation of acute lymphocytic leukemia. In the treatment and prophylaxis of meningeal leukemia. Greatest effect has been observed in palliation of acute lymphoblastic (stem cell) leukemias in children. In combination with other anticancer agents, methotrexate may be used for the induction of remission, but is most commonly used in maintenance of induced remissions. Methotrexate may be used alone or in combination with other antineoplastics in the management of breast cancer, epidermoid cancers of the head and neck, lung cancer (particularly squamous cell and small cell types), bladder cancer and osteogenic cancer. Methotrexate is effective in the treatment of the advanced stages (III and IV, Peters’ Staging System) of lymphosarcoma, particularly in children, and in advanced cases of mycosis fungoides.

Psoriasis: Because of the high risk attending its use, methotrexate is indicated only in the symptomatic control of severe recalcitrant, disabling psoriasis which is not adequately responsive to other forms of therapy, and only when the diagnosis has been established, as by biopsy and/or after dermatological consultation.

Rheumatoid Arthritis: Methotrexate can be used in the treatment of selected adults with severe rheumatoid arthritis, only when the diagnosis has been well-established according to rheumatological standards, with inadequate response to other forms of antirheumatic therapy, including full dose NSAIDs and usually a trial of at least one or more disease-modifying antirheumatic drugs.

Dosage and Administration

Dosage

Malignant tumors and hemoblastoses:

In polychemotherapy of malignant tumors and hemoblastoses the dosage of methotrexate has to be adjusted according to the indication, general condition and the blood counts of the patient. The administered dose in conventional low-dose MTX therapy (single dose lower than 100 mg/m²), medium-dose MTX therapy (single dose 100 mg/m²–1000 mg/m²) and high-dose MTX therapy (single dose higher than 1000 mg/m²) depends on the respective therapy protocol.

The following dosage instructions are only guidelines:

Conventional dose of methotrexate therapy – no calcium folinate rescue required:
15–20 mg/m² IV - twice weekly
30–50 mg/m² IV - once weekly
15 mg/m²/day IV/IM - given at 2–3 weeks intervals

Intermediate dose of methotrexate therapy:

50–150 mg/m² IV injection; no calcium folinate rescue required, given at 2–3 weeks intervals
240 mg/m² IV infusion over 24 h; calcium folinate rescue required, given at 4–7 days intervals
500–1000 mg/m² IV infusion over 36–42 h; calcium folinate rescue required, given at 2–3 weeks intervals

High-dose methotrexate therapy

– calcium folinate rescue required:
1–12 gm/m² IV over 1–6 hours, given at 1–3 weeks intervals

For intrathecal or intraventricular methotrexate therapy a maximum dose of 15 mg/m² is administered.

Intrathecal route of administration: 0.2–0.5 mg/kg or 8–12 mg/m² methotrexate is administered every 2–3 days, after disappearance of the symptoms at weekly intervals, and subsequently at monthly intervals until CSF findings return to normal. Prophylactic intrathecal instillation should be carried out every 6–8 weeks.

In severe, generalized, therapy-resistant psoriasis vulgaris including psoriatic arthritis and other autoimmunopathies:

It is recommended that a test dose of 5-10 mg may be parenterally administered one week prior to initiation of therapy, in order to detect idiosyncratic adverse effects. The recommended initial dose is 7.5 mg methotrexate once weekly. The dose should be increased as necessary but should not exceed a maximum weekly dose of 25 mg of methotrexate.

Dosage should be adjusted according to the general condition of the patient. Response to treatment can be expected after approximately 2-6 weeks. Once the desired therapeutic result has been achieved, dosage should be reduced gradually to the lowest possible effective maintenance dose.

In therapy-resistant rheumatoid arthritis:

Generally 7.5–15 mg methotrexate administered IM initially, as a massive-dose therapy once weekly. Dosage can be increased by 2.5 mg weekly, to a maximum of 25 mg weekly.

Response to treatment can be expected after approximately 4-8 weeks. Once the desired therapeutic result has been achieved, dosage should be reduced gradually to the lowest possible effective maintenance dose.

In patients with impaired renal function the therapy risk should be carefully considered and the dosage should be reduced correspondingly if required.

Method of Administration

Methotrexat "EBEWE" 50 mg can be administered IM, IV (as bolus injection or infusion), intra-arterially, intrathecally and intraventricularly.

Methotrexat "EBEWE" 500 mg, 1000 mg and 5000 mg – concentrate for infusion has to be diluted with standard solutions for infusions before administration according to therapy protocol and duration of infusion. Use 5% glucose solution, Ringer’s lactate or physiological saline solution.

Generally 1–2% methotrexate solution is administered (in osteosarcoma higher concentrations are described in the literature). These methotrexate solutions for infusion are stable at room temperature over 24 hours when exposed to light or protected from light. If longer infusion period is required, the infusion bags/bottle should be changed. Dosages higher than 100 mg/m² are generally administered as IV infusion.

Methotrexat "EBEWE" Pre-filled Syringe: Should be given by IV or IM.

Use only clear and freshly prepared solutions.

Avoid contact with skin or mucosa.

For single use only!

Contraindications

- Known hypersensitivity to any component of the drug
- Severe hepatic and renal impairment (serum creatinine > 2 mg%: contraindication; serum creatinine 1.5–2 mg%: dose to be reduced to 25% of the stated dose)
- Alcoholism
- Diseases of the hematopoietic system (bone marrow hypoplasia, leucopenia, thrombocytopenia, anemia)
- Existing infections
- Ulcers of the oral cavity and gastrointestinal tract
- Fresh surgical wounds
- Pregnancy and lactation (use of reliable method of contraception is mandatory before, during and after methotrexate therapy both in men and women.)

Particular care should be taken in impairment of bone marrow after an intensive radiotherapy, chemotherapy and/or prolonged pretreatment with drugs impairing bone marrow (sulphonamides, chloramphenicol, pyrazole derivatives, indomethacin, diphenylhydantoin); patients with poor general health, children and the elderly.

Methotrexate should not be used for the treatment of rheumatoid arthritis or psoriasis vulgaris in patients with pre-existing severe lung disease.

Caution should be exercised in patients with third space fluid collections (ascites, pleural effusion, seroma at site of operative wounds), since excretion of methotrexate may be reduced resulting in increase of toxicity.

Warnings and Precautions

Methotrexate should be administered only under the supervision of a qualified physician experienced in the use of antineoplastic therapy.

Special care should be taken when methotrexate is co-administered with non-steroidal anti-inflammatory drugs (NSAIDs). Severe side effects including fatalities (after high doses of methotrexate) have been reported.

Consumption of alcohol even in low doses should be avoided.

The patient should be informed about possible risks (side effects). Contraindications and precautions for use must be strictly observed because of possible severe (under particular circumstances lethal) toxic reactions.

Plasma concentration of methotrexate

- Higher than 1–2 times 10^{−9} mol/l (24 hours after initiating methotrexate therapy)
- Twice 10^{−6} mol/l (48 hours after initiating methotrexate therapy)
- 10^{−7} mol/l (72 hours after initiating methotrexate therapy)

indicate an increased risk of intoxication (myelosuppression, mucositis) and require a long-lasting and high dose of calcium folinate rescue therapy.

In patients with impaired renal functions methotrexate dosage has to be reduced accordingly.

In the case of high dose of methotrexate the creatinine clearance should be at least 75% of the normal value (50 ml/min/m² resp. 90 ml/min).

An intermediate dose of methotrexate (> 100 mg/m²) should not be prescribed if the creatinine clearance is reduced below 50% of the normal value (< 35 ml/min/m² resp. < 60 ml/min), unless daily determination of serum creatinine, methotrexate levels and calcium folinate rescue performed till the methotrexate levels decrease below 10^{−7} mol/l.

During the conventional dose of methotrexate a dose reduction of 50% is recommended if the serum creatinine values are 1. 2–2 mg/dl and cessation of therapy is recommended if serum creatinine values exceed 2 mg/dl.

Prerequisites for a medium or high-dose methotrexate administration:

- Adequate availability of calcium folinate for subsequent rescue therapy
- Rapid determination of methotrexate serum levels
- Availability of hemodialysis
- Autologous bone marrow or blood supplies, leukocytes and platelet concentrates

Pretreatment examinations and safety precautions:

- Exclusion of renal and liver impairment and disturbances of the hemopoietic system (renal and liver function tests, complete blood counts).
- Before treatment of rheumatoid arthritis with methotrexate in patients with hepatic disease a liver biopsy should be performed.
- Pregnancy should be excluded.

For prevention of intrarenal precipitation of methotrexate or its metabolites and for prophylaxis and treatment of hyperuricemia resulting from destruction of the cell nucleus, forced hydration and alkalization of the urine (by infusion of NaHCO₃ solution, 20–25 mmol/l in an amount of 3 l/m²/24 hours) 24 hours before and up to 24 hours after methotrexate administration is required.

If necessary 150–220 mg/m²/day acetazolamide or allopurinol: 8 mg/kg/day can be used.

An intermediate and high-dose methotrexate therapy should not be initiated when urinary pH values are below 7.0. The alkaline status of the urine must be controlled at least during the first 24 h after initiation of methotrexate administration (pH value ≥ 6.8).

Monitoring of methotrexate serum levels is mandatory immediately after cessation of methotrexate administration, as well as 24 h, 48 h and 72 h afterwards. On the basis of methotrexate serum levels, the occurrence of signs of toxicity can be inferred and the calcium folinate dosage can be adjusted.

During the intrathecal administration systemic side effects may occur.

A careful clinical examination of the patients, particularly inspection of the oral cavity, pharynx and larynx for changes in mucosa, regular monitoring of leucocytes and thrombocytes (daily up to 3 times weekly), complete blood count (once weekly), renal and liver functions should be performed.

During long-term or high-dosage therapy, bone marrow biopsies may be necessary. In severe leucopenia the risk of an infection should be borne in mind. In case of infection, therapy should be stopped and appropriate antibiotic therapy should be instituted. In severe cases of myelosuppression the transfusion of blood, leucocytes and thrombocytes may be necessary.

Drug Interactions

Several drugs may cause interactions (mainly pharmacokinetic) during concomitant administration of methotrexate.

The activity of methotrexate is increased by:

Inhibition of the renal excretion of methotrexate with non-steroidal anti-inflammatory drugs, salicylates, sulphonamides, probenecid, cephalothin, penicillin, carbenicillin, ticarcillin, para-aminohippuric acid.

Drugs which are involved in the active tubular secretion impair the elimination of methotrexate and therefore cause an increased plasma concentration.

The displacement of the methotrexate which is bound to plasma proteins leads to a higher free concentration in the plasma, e.g. with salicylates, sulfisoxazole, sulfafurazole, doxorubicin, bleomycin, cyclophosphamide, phenytoin, barbiturates, tranquilizers, tetracyclines, chloramphenicol, p-aminobenzoic acid, oral antiabetics (chlorpropamide, amidopyrine derivatives), diuretics.

Increase of the intracellular accumulation of methotrexate and methotrexate polyglutamates, e.g. with vinca alkaloids, epipodophyllotoxins, probenecid.

The activity of methotrexate is decreased by:

Inhibition of the intracellular uptake of methotrexate (corticosteroids, L-asparaginase, bleomycin, penicillin); increase of the dihydrofolate reductase concentration (triamterene) or increase of the intracellular purine concentration (allopurinol); vitamin preparations which contain folic acid or its derivatives (especially folic acid).

Drugs with known hepatotoxicity should not be administered concomitantly with methotrexate due to increased risk of hepatotoxicity.

Drugs with folic acid antagonist activity (pyrimethamine, trimethoprim) may increase the toxicity of methotrexate.

The myelosuppressive activity can increase due to long-lasting pretreatment with myelosuppressive substances (e.g. sulphonamide, chloramphenicol, pyrazole derivatives, indomethacin, and diphenylhydantoin).

Methotrexate can enhance the activity of coumarin-like oral anticoagulants (the prothrombin time is prolonged due to a reduced decomposition of coumarin derivatives). During simultaneous parenteral administration of acyclovir and intrathecal administration of methotrexate, neurological disorders can not be excluded.

Methotrexate may impair the immunologic reaction to vaccinations and may lead to severe complications. Therefore vaccinations should not be carried out during methotrexate therapy.

According to the type and intensity of the myelosuppressive therapy of the disease and other factors the ability to respond normally to vaccination may take 3–12 months. Leukemia patients in remission should not be vaccinated with live vaccines at least 3 months after the last dose of methotrexate.

The use of nitrous oxide anesthesia potentiates the effect of methotrexate on folate metabolism, yielding severe unpredictable myelosuppression and stomatitis. This effect can be reduced by the use of folic acid rescue.

Amiodarone administration to patients receiving methotrexate treatment for psoriasis has induced ulcerated skin lesions.

An increased risk of hepatotoxicity has been reported when methotrexate and etretinate are given concurrently.

Pregnancy and Lactation

Methotrexate is a teratogenic drug; abortion, fetal death and/or congenital abnormalities have been reported. Therefore, it is not recommended in women of childbearing potential unless the potential benefits can be expected to outweigh the risks. If the drug is used during pregnancy for antineoplastic indications, or if the patient becomes pregnant while taking this drug, the patient should be informed on the potential hazard to the fetus.

For the management of psoriasis or rheumatoid arthritis, methotrexate therapy in women should be started immediately following a menstrual period.

Appropriate measures should be taken in men or women to avoid conception during and for at least 6 months following cessation of methotrexate therapy.

Effects on the Ability to Drive and Use Machines

The ability of patients to drive or operate machinery may be impaired.

Adverse Effects

Many side effects of methotrexate therapy are unavoidable being due to the pharmacological actions of the drug. However, these adverse effects are generally reversible if detected early. The major toxic effects of methotrexate occur in normal, rapidly proliferating tissues, particularly bone marrow and the gastrointestinal tract. Ulcerations of the oral mucosa are usually the earliest signs of toxicity. The most commonly reported adverse effects are difficulty in swallowing, ulcerative stomatitis, pharyngitis, leucopenia, thrombocytopenia, nausea, vomiting and abdominal distress; however, as for other cytotoxic drugs, different toxicities may occur with different frequency/intensity according to different doses/routes of administration.

Other reported adverse effects include malaise, undue fatigue, chills and fever, dizziness, decreased resistance to infection, tinnitus, blurred vision and eye discomfort. The incidence and severity of side effects appear to be dose-related.

Other side effects can be classified as follows:

Skin and Hypersensitivity Reactions: Erythema, exanthema, pruritis, photosensitivity, alopecia, telangiectasias, dyschromia, ecchymosis, acne, furunculosis. Severe toxic manifestations like vasculitis, severe herpeticform skin eruptions and Lyell’s syndrome may appear. Psoriatic lesions can increase by simultaneous UV radiation therapy.

Blood: Bone marrow depression, leucopenia, neutropenia, thrombocytopenia, anemia and hypogammaglobulinemia are expected following methotrexate therapy. The nadir of circulating leukocytes, neutrophils and platelets usually occurs between 5 and 13 days after an IV bolus dose (with recovery between 14 to 28 days). Leukocytes and neutrophils may occasionally show two depressions, the first occurring in 4–7 days and a second nadir after 12–21 days, followed by recovery. Clinical sequelae such as fever, infections, septicemia and hemorrhage from various sites may be expected. Megaloblastic anemia has also been reported, mainly in elderly patients receiving long-term weekly methotrexate therapy. Folate supplementation may permit continuation of methotrexate therapy with resolution of anemia.

Alimentary System: Gingivitis, glossitis, pharyngitis, stomatitis, anorexia, vomiting, diarrhea, hematemesis, melena, gastrointestinal ulceration and bleeding, enteritis, intestinal perforation, abdominal distress and anorexia may occur. Methotrexate administration has been associated with acute and chronic hepatotoxicity: acute liver atrophy, necrosis, fatty metamorphosis, periportal fibrosis or hepatic cirrhosis. Alteration of liver function tests (increases in transaminases and LDH levels) is commonly reported but usually resolves within one month after cessation of therapy. A more important hepatic fibrosis or cirrhosis may follow long-term (2 years or longer) treatments and high cumulative drug doses. The risk of developing chronic hepatotoxicity in psoriatic patients seems to be correlated not only to the cumulative dose of the drug but also to the presence of concurrent conditions such as alcoholism, obesity, diabetes, advanced age and the use of arsenical compounds.

Urogenital System: Renal failure, azotemia, cystitis, hematuria, defective oogenesis or spermatogenesis, transient oligospermia, urogenital/menstrual dysfunction, vaginal discharge, infertility, abortion, fetal defects, severe nephropathy have been reported.

Pulmonary System: Interstitial pneumonitis, interstitial fibrosis, reversible eosinophilic pulmonary infiltrates may occur. Deaths have been reported and chronic interstitial obstructive pulmonary disease has occasionally occurred. Manifestations of methotrexate-induced pulmonary toxicity commonly include fever, cough (especially dry and non-productive), dyspnea, chest pain, hypoxemia and/or radiological evidence of pulmonary infiltrates (usually diffuse and/or alveolar).

Central Nervous System: Headaches, drowsiness, blurred vision, aphasia, hemiparesis and convulsions have occurred. Convulsions, paresis, Guillain-Barré syndrome and increased cerebrospinal fluid pressures have followed intrathecal administration. Neurotoxicity is reported in patients receiving intrathecal or high-doses of methotrexate. Chemical arachnoiditis is manifested by headache, back pain, nual rigidity. A subacute form of toxicity may be characterized by varying degrees of paresis. Paraplegia and increased CSF pressure have also been reported. A delayed syndrome, occurring months to years after treatment, is characterized by necrotizing leukoencephalopathy. The syndrome may begin insidiously and progress to confusion, stupor, seizures, ataxia and dementia. The effects are dose-related and occur particularly when intrathecal methotrexate is given at doses greater than 50 mg in combination with cranial irradiation and systemic methotrexate therapy. Cognitive impairment has been recorded in children who received intrathecal methotrexate together with cranial irradiation.

Carcinogenicity: Cytotoxic drugs have been reported to be associated with an increased risk of development of secondary tumors in humans. Evidence of chromosomal damage to animal somatic cells and human bone marrow cells has been reported with methotrexate.

Other Reactions related to methotrexate use include pneumonitis, metabolic changes, precipitation of diabetes, osteoporotic effects, including aseptic necrosis of the femoral head, abnormal changes in tissue cells and even sudden death.

Overdose

Calcium folinate is the antidote for neutralizing the immediate toxic effects of methotrexate on the hematopoietic system.

When large doses or overdoses are given, calcium folinate may be administered by intravenous infusion in doses up to 75 mg within 12 hours, followed by 12 mg intramuscularly every 6 hours for 4 doses. When average doses of methotrexate appear to have an adverse effect, 6–12 mg of calcium folinate may be given intramuscularly every 6 hours for 4 doses. In general, where overdosage is suspected, the dose of calcium folinate should be equal to or higher than the offending dose of methotrexate and should be administered as soon as possible; preferably within the first hour and certainly within 4 hours after which it may not be effective.

Other supporting therapy such as blood transfusion and renal dialysis may be required. Effective clearance of methotrexate has been reported with acute, intermittent hemodialysis using a high-flux dialyser.

Pharmaceutical Properties

Properties and Efficacy

Methotrexate is a folic acid antagonist with cytotoxic activity belonging to the group of antimetabolites. Methotrexate acts mainly in the S-phase of the cell division. It inhibits competitively dihydrofolate reductase and the reduction of dihydrofolic acid (FH₂) to tetrahydrofolic acid (FH₄).

Activated reduced folate derivatives are necessary for the transmission of C1 units and the synthesis of pyrimidine, purine and amino acids. Therefore methotrexate induces an inhibition of the DNA, RNA and protein synthesis through the intracellular decrease of FH₄ and activated reduced folate derivatives.

The cytotoxic activity of methotrexate correlates *in vitro* with the inhibition of the DNA synthesis.

Rapidly proliferating tissues like malignant cells, bone marrow, fetal cells, skin epithelium and mucosa are generally more sensitive to methotrexate. The cell proliferation is accelerated in malignomas and methotrexate can therefore influence persistently the malignant growth without causing irreversible damage to the normal tissue. In psoriasis cell proliferation of the epithelium as compared to normal skin is increased. This difference in the cell proliferation rate is the reason for the use of methotrexate in severe recalcitrant disabling psoriasis and arthritis psoriatica. The activity of methotrexate can be neutralized with the administration of folinic acid (as calcium folinate). Folinic acid is metabolized intracellularly through N₅-methyl-tetrahydrofolic acid into tetrahydrofolic acid and N₅,10-methylen-tetrahydrofolic acid and causes filling of the intracellular pool of reduced folate derivatives avoiding the inhibition of the dihydrofolate reductase by methotrexate.

Pharmacokinetics

In high-dose methotrexate therapy plasma concentrations of 10⁻³ mol/l were reached immediately after infusion. After IV administration of methotrexate the extracellular distribution is very rapid; in the total fluid content of the body the distribution is in volume of approx. 76% of the body weight. With parenteral administration, therapeutically insufficient concentrations are reached in the CSF due to an impaired crossing of the blood-brain barrier. High concentrations can be obtained by intrathecal administration, if required.

After IV administration a triphasic pathway is assumed for the plasma concentrations of methotrexate with medium half-life times of 0.75, 3.49 and 26.99 hours whereby there are wide fluctuations in the third phase (6–69 hours).

After the administration of methotrexate as IV bolus injection or short-term infusion 80–95% of methotrexate is excreted via kidney unchanged within 24–30 hours with normal renal function.

Particularly with impaired renal function and also with gastrointestinal obstruction (ileus) and if a "third space" is present as a reserve compartment in which MTX can accumulate (such as ascites and/or pleural effusions), the total clearance is reduced and an intensified and prolonged action of MTX is observed.

After intrathecal methotrexate administration a slow resorption in the plasma compartment occurs and leads to possible prolonged toxic plasma levels, 7-hydroxy-methotrexate and 2,4-diamino-N₁₀-methyl-pterotic acid (DAMPA) were found as metabolites in the plasma and urine. Methotrexate, 7-hydroxymethotrexate and DAMPA are slightly soluble in acidic urine; therefore a corresponding hydration and alkanisation of the urine are absolutely required during high-dose methotrexate therapy to avoid acute renal insufficiency due to intrarenal precipitation.

Methotrexate is bound to serum protein in a rate of 50–70%.

Pharmaceutical Particulars

List of Excipients

Sodium Chloride, Sodium Hydroxide for pH adjustments, Water for Injection

Incompatibilities

Known incompatibilities include strong oxidants and acids. Immediate precipitation or turbidity occurs with chlorpramazine hydrochloride, droperidol, idarubicin, metoclopramide hydrochloride, heparin solution, prednisolone sodium phosphate, promethazine hydrochloride, cytarabine, and fluorouracil.

Shelf Life

2 years.

Storage

Store at room temperature, do not exceed 25° C, do not freeze, protect from light. Keep in a safe place out of the reach of children.

Presentations

Vials

Methotrexat "EBEWE" 50 mg - 1 vial of 5 ml
Methotrexat "EBEWE" 500 mg - 1 vial of 5 ml
Methotrexat "EBEWE" 1000 mg - 1 vial of 10 ml
Methotrexat "EBEWE" 5000 mg - 1 vial of 50 ml

Pre-filled Syringes

1 pre-filled syringe of 0.75 ml contains 7.5 mg methotrexate
1 pre-filled syringe of 1.00 ml contains 10.00 mg methotrexate
1 pre-filled syringe of 1.50 ml contains 15.00 mg methotrexate
1 pre-filled syringe of 2.00 ml contains 20.00 mg methotrexate
Methotrexat "EBEWE" is available in pre-filled syringes of colourless glass (type I according to E.P.) with a capacity of 1.25 ml, 2.25 ml or 3.00 ml, an elastomeric tip cap and elastomeric plunger stopper.
Each box contains 1 pre-filled syringe with solution for injection, single use injection needles and alcohol pads.

Instructions for Use/Handling

- Parenteral methotrexate preparations do not contain an antimicrobial preservative. Any unused solution should be discarded.
- Parenteral methotrexate preparations are stable for 24 hours when diluted with the following intravenous solutions for infusion: 0.9% sodium chloride, glucose, sodium chloride and glucose, compound sodium chloride (Ringer’s injection), compound sodium lactate (lactated Ringer’s injection).
- Do not mix methotrexate with other drugs in the same infusion bag.
- Cytotoxic drugs should be handled only by trained personnel and in a designated area.
- The work surface should be protected by disposable plastic backed absorbent paper.
- Protective clothing (goggles, gowns and disposable gloves and masks) should be worn by staff handling parenteral methotrexate.
- Methotrexate is not vesicant and should not cause harm if it comes in contact with the skin. However, it should be washed off with water immediately. Any transient stinging may be treated with bland cream. If there is any danger of systemic absorption of significant quantities of methotrexate by any route, calcium folinate cover should be given.
- Cytotoxic preparations should not be handled by pregnant staff.
- All items used for reconstitution, administration or cleaning, including gloves, should be placed in high risk, waste disposal bags for high temperature incineration.
- Any spillage or waste material may be disposed of by incineration.

Manufacturer: EBEWE Pharma Ges.m.b.H., A-4866 Unterach, Austria

Licence Holder: Pharmalogic Ltd., P.O. Box 3838, Petah-Tikva 49130

The format of this leaflet was determined by the Ministry of Health and its content was checked and approved in December 2009.